What are the challenges and future directions for CDK inhibitors in cancer treatment?
One of the main challenges in using CDK inhibitors is the development of resistance. Cancer cells can develop various mechanisms to evade the inhibitory effects of these drugs, such as mutations in CDKs or cyclins, activation of alternative signaling pathways, or upregulation of efflux pumps that remove the drug from cancer cells. Ongoing research is focused on identifying these resistance mechanisms and developing combination therapies to overcome them. Additionally, efforts are being made to discover more selective CDK inhibitors with fewer side effects.
